March 13, 2020 8:33am

And everything else, we believe about this market however, what’s gone way down should eventually go up, the question is when? There are no guarantees and volatility could turn down again

Pre-open indications: 11 BUYs for consideration

March continues as a rollercoaster theme month – my version of the morning’s numbers is written to be informative; it’s what is about what happened 

Dow future are UP +5.30% (+1110 points), S&P futures are UP +5.13% (+126 points) and NASDAQ futures are UP +5.66% (+407 points)

 

U.S. stock futures were pointing to the upside yet still volatile after the indexes on Thursday suffered big losses on Thursday their worst session since 1987;

European stocks attempted to rally in early trade after their worst sell-off in history, as the rapid spread of the coronavirus continues to dominate investor sentiment with the pan-European Stoxx 600 climbing +2.1% after having dived -11% in the previous session;

Asia Pacific markets traded shifting and wildly on Friday, with Australian shares staging a dramatic 4.42% comeback. in India, the Nifty 50 rose into positive territory as it jumped +2.15%. In Japan, the Nikkei 225 fell -6.08%. Mainland Chinese stocks saw losses on the day as the MSCI Asia ex-Japan index slipped -0.85%.

 

Henry’omics:

Indexes struggle for traction as dejected and despondent investors head to a desperately needed break from the week of market disruption!

U.S. stock futures were pointing at a rebound attempt on Friday, after a week of dramatic losses across the globe; European markets are rising, but Asian markets got hammered!

My constant and reiteration … investors must now take more time to review their portfolio and make sure they’re comfortable with their level of risk!

Back to the pandemic that’s dominating market volatility, the coronavirus has now infected more than 128,000 people worldwide, with 4,720 deaths, according to the latest figures from Johns Hopkins University. Italy remains the worst impacted country in Europe and is now facing total shutdown, with cases surpassing 15,000 and 1,016 deaths confirmed as of 6 p.m. on Thursday. <CNBC>

 

An interesting quotation as related to markets, our universe of cell and gene therapy companies, “the biggest issue isn’t totally the coronavirus, it’s the liquidity crisis”.

What should, we now be doing – staying healthy, get through this period and hope that by new practices of living … and be ready for this market to turn.

 

Thursday night’s title: “the sector was surrounded by strong winds in the eye of the storm. Q4 and FY19 “numbers” are being “masked” by the motion and impact of coronavirus pricing disruption – thank electronic trading and algorithms pursuing their capacity of emotionless profit taking”

  • the NASDAQ closed DOWN – 750.25points (-9.43%);
  • the IBB closed down -8.85% and XBI closed down -10.89%;
  • the close was negative with an A/D line of 2/33, 0 flat of 35 covered;
  • the range of the 2-upside was +3.39% (ADRO) to +6.57% (PSTI) while the 33-downside ranged from -3.14% (BSTG) to -29.47% (BLFS); 
  • 1 out of the 2-upside had higher than the 3-month average volume;
  • 26 out of the 33-downside had higher than the 3-month average volume;

 

Q1:

March registered 6 negative and 3 positive closes

February registered 9 negative, 9 positive closes, 3 vacation days and 1 holiday.

January registered 9 negative, 10 positive closes and 2 holidays.

 

Q4:

  • December register 11 negative and 10 positive closes
  • November registered 1 holiday, 12 positive and 8 negative close;
  • October registered 10 positive, 1 neutral and 14 negative closes;

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Pre-open indications: a day to sit on one’s hands and watch and wait for electronic trading to accelerate pricing in our cell and gene therapy companies

I’d be “considering” BUYING: BLUE, GBT, ALNY, RGNX, CRSP, IONS, FIXX, BLFS, RENE.L, VCEL and RARE

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.